Measurable disease as defined by RECIST v1.1
Patient much have measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1
SAFETY RUN-IN: Have either evaluable disease, or have measurable clinical disease: measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)
RANDOMIZED PHASE II CLINICAL TRIAL: Have measurable clinical disease: Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST (version v1.1)
Measurable disease as defined by RECIST
Measurable disease as defined by RECIST 1.1 is required (Part 2)
Participants must have measurable extracranial disease as defined by RECIST 1.1
One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1. At least one lesion accessible for biopsy
Participant must have measurable disease outside the field of radiation as defined by RECIST 1.1
Part B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.
Presence of at least one measurable lesion as defined by RECIST 1.1
Measurable disease, as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1
Measurable or non-measurable disease, as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Most recent imaging shows measurable disease as defined by RECIST 1.1
Have measurable clinical disease: measurable disease, defined as at least 1 measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)
Patients must have measurable disease as defined by RECIST v1.1
Radiologically measurable disease in the pancreas >= 1 cm, as defined by RECIST v1.1
Patients must have measurable disease as defined by RECIST (see Section 6).
All patients must have measurable disease as defined by RECIST 1.1; patients must also have evidence of disease progression by RECIST 1.1 within 6 months of first dose of study drug
Patients must have at least one measurable lesion as defined per RECIST 1.1
Subjects must have measurable disease as defined by RECIST 1.1
Patients may have measurable or non-measurable disease as defined by RECIST 1.1.
At least one measurable lesion as defined by RECIST 1.1
Patients may have measurable or non-measurable disease as defined by RECIST 1.1.
Measurable disease by CT or MRI, as defined by RECIST v1.1
Has ?1 measurable lesion as defined by RECIST 1.1 on imaging studies.
At least one measurable lesion as defined by RECIST 1.1
Patients must have at least one measurable or non-measurable lesion (dose escalation only) as defined by RECIST v1.1
Absence of RECIST, v. 1.1 defined measurable disease.
Participants must have at least a single (RECIST v1.1-defined) measurable lesion.
Subjects must have measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1
Measurable/assessable disease, as defined by RECIST v1.1.
Measurable disease, as defined by RECIST v1.1
Patients must have measurable disease as defined by RECIST 1.1.
Measurable disease as defined by RECIST 1.1
Measurable disease defined as at least one uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1
Measurable disease as defined by modified RECIST for MPM (Byrne and Nowak, 2004)
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1
Measurable disease as defined by RECIST 1.1.
Patients must have measurable disease, defined by RECIST 1.1
Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST.
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v1.1
Measurable disease, as defined by RECIST v 1.1
Has at least 1 radiologically measurable lesion as defined by RECIST 1.1
Measurable disease as defined by RECIST v1.1
Must have measurable disease as defined by RECIST 1.1.
Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST 1.1
At least 1 measurable lesion as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease defined as one or more target lesions according to RECIST
Measurable disease defined by RECIST v1.1
Measurable disease as defined by the RECIST v1.1.
Patient must have measurable disease as defined by RECIST 1.1.
During the dose expansion part of study, all patients must have at least one measurable lesion as defined by RECIST criteria.
At least one measurable lesion as defined by RECIST v1.1
Measurable disease as defined by RECIST v1.1
Measurable disease as defined by RECIST 1.1 within 28 days prior to registration
Has At least one measurable lesion as defined by RECIST criteria
Measurable disease, as defined by RECIST v1.1
Presence of measurable or non-measurable lesions as defined by irRC-RECIST